華安 (6657) shareholders to participate in 源華智醫’s year 115 cash capital increase; payment call period runs from 9/11 to 10/12 — Global Bio & Investment Monthly
Summary not yet available
Companies mentioned：華安、源華智醫
2026-09-08 21:00–24:00 JST
104 received, 104 listed, 5 sources ・ Page 2 of 2
One place for news and notices from 2 countries/regions: Taiwan, 87 items from 4 sources; Japan, 17 items from 1 source.
One edition every 180 minutes: every item from every source received in the period, with the original link.
Taiwan | 環球生技月刊 (continued)（9）
One-year study results for 鼎晉’s long-acting botulinum toxin type A show an adverse event rate of 0.7% — Global Bio & Investment Monthly
Summary not yet available
Facts
- The adverse event rate was 0.7%
- The study enrolled 200 participants
- A total of 432 treatment sessions have been completed
- OBI-858, a 760kDa long-acting botulinum toxin type A drug
Companies mentioned：鼎晉生技
The 15th class of ITRI fellows announced; Taipei Veterans General Hospital President Chen Wei-ming selected in recognition of his contributions to medicine — Global Bio & Investment Monthly
Summary not yet available
Facts
- 3 newly appointed fellows
Companies mentioned：工業技術研究院、台積電、瑞昱半導體、臺北榮民總醫院
保瑞’s August revenue hit a historic second-high of NT$2.18 billion, up 59% year on year - Global Bio & Investment
Summary not yet available
Facts
- Self-reported consolidated revenue for August was NT$2.18 billion
- Year-on-year growth of 59.22%
- Revenue for the first 8 months of this year totaled NT$13.979 billion
- Up 6.09% year over year
Companies mentioned：保瑞藥業、保瑞